Table 2

Change in wtSDS and lung function over the preceding year by glycemic groups

Change in*Cystic fibrosis–specific OGTT cutoffWHO categories based on BG120Cystic fibrosis–specific CGM-based cutoff
BGmax ≥8.2 mmol/lBGmax <8.2 mmol/lPIGT: 7.8–11 mmol/lNGT: <7.8 mmol/lPCGM >7.8 mmol/l ≥4.5%CGM >7.8 mmol/l <4.5%P
n (%)21/31 (68)†10/31 (32)13/31 (42)†18/31 (58)15/23 (65)†8/23 (35)
wtSDS−0.3 ± 0.40.0 ± 0.40.04−0.2 ± 0.4−0.2 ± 0.40.94−0.3 ± 0.40.1 ± 0.20.01
%FEV1−6 ± 7−4 ± 110.48−6 ± 7−5 ± 90.83−6 ± 7−2 ± 110.31
%FVC−4 ± 70.5 ± 100.21−5 ± 6−1 ± 90.21−4 ± 71 ± 100.13
  • Data are means ± SD unless otherwise indicated. Change in weight and lung function in the preceding 12 months in 31 patients with cystic fibrosis, excluding the 2 patients with BG120 min ≥11.1 mmol/l (diabetic by WHO criteria) are shown. Groups are compared according to three different glycemic cutoffs.

  • *Over the preceding year.

  • †Excluding 2 patients (BG120 min >11.1 mmol/l).